--- title: "CAR-T Cell Therapy Hub" canonical: "/car-t-cell-therapy-hub" published: 2026-09-18 --- # CAR-T Cell Therapy Hub ## Hero CAR-T CELL THERAPY HUB · RESOURCE LIBRARY Guiding Every Step of the CAR-T Cell Therapy Journey Curated, practice-ready resources supporting the safe, effective implementation of CAR-T cell therapy — organized into Clinical Education, Agent-Specific Resources, and Example SOPs & Documents. 4 3 7 2 Toolkits Core Sections Agent Profiles Example SOPs ## Section Nav Clinical Education Agent-Specific Resources Example SOPs & Documents Recommended Reading ## CTA Outer CAR-T Patient Journey Referral Apheresis Manufacturing Bridging Therapy Lymphodepletion Infusion & Monitoring ## Clinical Education **Clinical Education-Anchor** 01 · FOUNDATIONS Clinical Education Foundational knowledge to help your team understand and operationalize CAR-T cell therapy. 01 02 03 Comparison of CAR-T Cell Therapies Managing CAR-T Immune-Related Adverse Events Outpatient CAR-T: Same Powerful Therapy, Different Care Model Compare approved CAR-T therapies by disease state, including dosing, safety, and manufacturing considerations. Explore outpatient CAR-T models, including patient selection, monitoring, escalation, and program readiness. Review recognition, grading, and management of CAR-T toxicities, including CRS and ICANS. View Resource → View Resource → View Resource → ## Agent-Specific Resources **Agent-Specific Resources-Anchor** 02 · UP CLOSE SERIES Agent-Specific Resources A comparison guide plus a closer look at every FDA-approved CAR-T therapy — target antigen, brand name, and where to go deeper. Obecatagene Autoleucel Target: CD19 View → AUCATZYL® Tisagenlecleucel View → Target: CD19 KYMRIAH® Axicabtagene Ciloleucel View → Target: CD19 YESCARTA® Brexucabtagene Autoleucel View → Target: CD19 TECARTUS® Lisocabtagene Maraleucel View → Target: CD19 BREYANZI® Idecabtagene Vicleucel Target: BCMA View → ABECMA® Ciltacabtagene Autoleucel Target: BCMA View → CARVYKTI® ## Example SOPs and Documents **Example SOPs & Documents-Anchor** 03 · REAL-WORLD PRACTICE Example SOPs & Documents Two standard operating procedures and three clinic implementation toolkits, shared by NCODA member practices. SOP Document CAR-T Center Coordination With a Community Cancer Center This example standard operating procedure (SOP) provides a framework for CAR-T centers to coordinate care with community cancer centers throughout referral, patient evaluation, bridging therapy, lymphodepletion, infusion, acute toxicity management, transition of care, and long-term follow-up. View Resource → SOP Document Community Practice Coordination With a CART-T Treatment Center This example standard operating procedure provides a framework for community oncology practices coordinating care with a CAR-T treatment center from early referral through long-term follow-up. View Resource → TOOLKIT Apheresis & Bridging Therapy Coordination Scheduling and coordinating cell collection and any bridging therapy before manufacturing. View Resource → TOOLKIT Infusion & Care Coordination Inpatient/outpatient coordination for the infusion day and immediate monitoring window. In Development → TOOLKIT Long-Term Follow-Up & REMS Compliance Ongoing monitoring requirements and REMS documentation for CAR-T recipients. In Development → TOOLKIT Long-Term Follow-Up & REMS Compliance Ongoing monitoring requirements and REMS documentation for CAR-T recipients. In Development → ## Recommended Reading **Recommended Reading-Anchor** RECOMMENDED READING Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544. 1 Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448. 2 Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638. 3 Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-716. 4 ## CTA Outer Help Build the CAR-T Cell Therapy Hub NCODA members can share protocols, request specific SOPs, or connect with our team. **Submit a Practice SOP** **Become a Member**